Shorla Oncology's Jylamvo (methotrexate) has received expanded FDA approval for treating pediatric patients with acute lymphoblastic leukemia (ALL) and polyarticular juvenile idiopathic arthritis (pJIA). This makes Jylamvo the only oral liquid formulation of methotrexate available for both adults and children.
The FDA's decision marks a significant advancement in pediatric care, addressing the unmet need for convenient methotrexate administration. Jylamvo's availability as an orange-flavored solution eliminates the need for crushing pills or compounding medications, simplifying the treatment process for young patients.
Clinical Basis for Approval
The approval is grounded in clinical trial data that established the safety and effectiveness of methotrexate in treating pediatric ALL and pJIA. While Jylamvo's specific formulation wasn't directly tested in these trials, the established efficacy of methotrexate provides a strong rationale for its use.
Sharon Cunningham, CEO of Shorla Oncology, emphasized the importance of this approval, stating that it "represents a critical step forward in addressing the unmet need of pediatric care in oncology and autoimmune diseases."
Advantages of Jylamvo
Jylamvo offers several advantages over traditional methotrexate formulations. Its liquid form is easier for children to swallow, improving adherence to treatment regimens. Additionally, Jylamvo remains stable at room temperature for 90 days after opening, removing the need for refrigeration and simplifying storage for patients and caregivers.
Rayna Herman, Chief Commercial Officer of Shorla Oncology, highlighted this benefit, noting that the room temperature stability "adds convenience for patients."
Safety Considerations
It is important to note that methotrexate carries risks of embryo-fetal toxicity, hypersensitivity reactions, and severe side effects. The prescribing information includes warnings about potential gastrointestinal, bone marrow, lung, liver, kidney, and skin-related adverse events. Patients should be closely monitored for infections and other complications during treatment.
Common side effects reported in clinical trials of methotrexate include leukopenia, ulcerative stomatitis, abdominal distress, and nausea. Clinically relevant side effects also included general discomfort, infection, fatigue, fever, chills, and dizziness.
Jylamvo is contraindicated in patients with a history of severe hypersensitivity to methotrexate, including anaphylaxis.
